Alpha Cognition (NASDAQ:ACOG) reported 40% sequential revenue growth in the first quarter of 2026, as executives said commercial adoption of its Alzheimer’s treatment ZUNVEYL continued to build across prescribers and long-term care facilities.
Chief Executive Officer Michael McFadden said the quarter marked the company’s fourth full quarter of commercialization for ZUNVEYL, which he described as “the first new oral Alzheimer’s treatment approved in more than 15 years.” Alpha Cognition generated net product revenue of $3.5 million in the quarter, up from $2.5 million in the fourth quarter of 2025.
